Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Comparison of antiproliferative effects of amlodipine and nebivolol against MCF-7 cells: An in vitro study

Hemalatha A, Pradeep Kumar B T, Vishnu Priya G, Latha Priya A, Vijaybabu K.




Abstract

Background: Breast cancer (BC) has become the most common cancer among women in India. Both amlodipine, belonging to calcium channel blockers, and nebivolol, belonging to the beta blockers class have proven anticancer mechanisms. However, the effect has not been compared between these drugs till now.

Aim and Objectives: The present study aims to compare the antiproliferation effects of amlodipine and nebivolol against human breast adenocarcinoma MCF-7 cells.

Materials and Methods: Cell viability assay was used to screen the antiproliferation effects of the study drug molecules in MCF-7 cell cultures. The IC50 values were derived graphically by plotting the cell viability against drug concentration.

Results: Both amlodipine and nebivolol exhibited dose-dependent cytotoxicity against BC cells. The IC50 of amlodipine was 166.6 μg/mL and nebivolol was 114.6 μg/mL.

Conclusion: In this study, nebivolol showed potent cytotoxicity compared to amlodipine. This inference may provide further insights into future drug research.

Key words: Breast Cancer Cells; Cell Viability Assay; Beta Receptors; Calcium Channels






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.